BernsKI. My life with adeno-associated virus: a long time spent studying a short genome. DNA Cell Biol, 2013; 32:342–347.
2.
KeelerAM, FlotteTR. Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): Where are we, and how did we get here?. Annu Rev Virol, 2019; 6:601–621.
3.
WilsonJM, FlotteTR. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther, 2020; 31:695–696.
4.
ShiehPB, BonnemannCG, Muller-FelberW, et al.Letter to the editor. Hum Gene Ther, 2020; 31:787.
5.
SrivastavaA. AAV vectors: are they safe?. Hum Gene Ther, 2020; 31:697–699.
SrivastavaA, LusbyEW, BernsKI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol, 1983; 45:555–564.
9.
SonntagF, SchmidtK, KleinschmidtJA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A, 2010; 107:10220–10225.
10.
OgdenPJ, KelsicED, SinaiS, et al.Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science, 2019; 366:1139–1143.
11.
BohlenMO, McCownTJ, PowellSK, et al.AAV capsid promoter interactions in the brain translate from rat to the non-human primate. Hum Gene Ther, 2020; 31:1155–1168.
SalganikM, AydemirF, NamHJ, et al.Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J Virol, 2014; 88:1071–1079.
14.
AydemirF, SalganikM, ResztakJ, et al.Mutants at the 2-fold interface of adeno-associated virus type 2 (AAV2) structural proteins suggest a role in viral transcription for AAV capsids. J Virol, 2016; 90:7196–7204.
15.
BuningH, SrivastavaA. Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev, 2019; 12:248–265.
